Clinical evaluation of celiprolol hydrochloride (Selectol®) to the hypertensive patients with type 2 diabetes - Combination therapy with Ca2+antagonist and/or ACE inhibitor

Meguro Shu, Takei Izumi

研究成果: Article


The aim of this study was to confirm the clinical efficacy, metabolic effects and safety of celiprolol, a selective β1-blocker with β2 agonist property, to essential hypertensive patients with diabetes aged 53 to 92 years (mean, 70 years), recognized insufficient antihypertensive effects by Ca2+antagonist and/or ACE inhibitor. Fifteen patients were administered celiprolol at daily dose of 100∼200 mg during six months. The obtained results were followed. Blood pressure decreased significantly from 164.8 ± 5.8/92.8 ± 3.0 mmHg to 151.7 ± 3.8/84.7 ± 3.6 mmHg after six months of treatment, respectively (p<0.05). On the oral glucose tolerance test, celiplorol had no influence to values of blood sugar and blood insulin. As well as HbA1c and Body mass index, no significant changes were observed. Total cholesterol and triglyceride decreased significantly from 218.9 ± 10.4 mg/dL and 125.3 ± 12.9 mg/dL to 193.8 ± 10.4 mg/dL and 88.6 ± 4.1 mg/dL, respectively (p<0.05). HDL cholesterol increased from 52.9 ± 3.8 mg/dL at the before treatment to 54.4 ± 6.9 mg/dL at the six months after treatment, but not significant. No side effcts were noted in all patients. The above results indicated that celiprolol is useful β-blocker to essential hypertensive patients with type 2 diabetes.

ジャーナルTherapeutic Research
出版物ステータスPublished - 2002 1 1


ASJC Scopus subject areas

  • Medicine(all)